These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31985552)

  • 1. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
    Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2019 Feb; 41(1):86-90. PubMed ID: 30489548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Genetic Polymorphisms of ABCB1, ABCG2, and SLC22A1 on the Steady-State Plasma Concentrations of Lamotrigine in Treatment-Resistant Depressed Patients Treated With Lamotrigine Augmentation Therapy.
    Tomori Y; Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Clin Neuropharmacol; 2024 Sep-Oct 01; 47(5):163-167. PubMed ID: 39171842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study.
    Nagai G; Mihara K; Kagawa S; Nakamura A; Suzuki T; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 76(4):187-192. PubMed ID: 29961057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.
    Ketter TA; Greist JH; Graham JA; Roberts JN; Thompson TR; Nanry KP
    J Clin Psychiatry; 2006 Mar; 67(3):400-6. PubMed ID: 16649826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine Induces Hair Loss in a Patient With Treatment-Resistant Major Depressive Disorder.
    Solmi M; Tamiello GI; Manuli G
    Am J Ther; 2017; 24(5):e611-e612. PubMed ID: 28346304
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review.
    Kumar R; Nuñez NA; Prokop LJ; Veldic M; Betcher H; Singh B
    J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):681-686. PubMed ID: 34459434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamotrigine for people with borderline personality disorder: a RCT.
    Crawford MJ; Sanatinia R; Barrett B; Cunningham G; Dale O; Ganguli P; Lawrence-Smith G; Leeson VC; Lemonsky F; Lykomitrou-Matthews G; Montgomery A; Morriss R; Munjiza J; Paton C; Skorodzien I; Singh V; Tan W; Tyrer P; Reilly JG
    Health Technol Assess; 2018 Apr; 22(17):1-68. PubMed ID: 29651981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.
    Pinto OC; Akiskal HS
    J Affect Disord; 1998 Dec; 51(3):333-43. PubMed ID: 10333987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of clozapine for resolving lamotrigine-induced skin lesions caused by schizophrenia treatment.
    Tsai LH; Lin JW
    Psychiatr Danub; 2019 Sep; 31(3):362-365. PubMed ID: 31596832
    [No Abstract]   [Full Text] [Related]  

  • 15. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder.
    Sharma V; Doobay M
    CNS Spectr; 2019 Aug; 24(4):390-394. PubMed ID: 30086812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine-associated rash: to rechallenge or not to rechallenge?
    Lorberg B; Youssef NA; Bhagwagar Z
    Int J Neuropsychopharmacol; 2009 Mar; 12(2):257-65. PubMed ID: 18845017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial.
    Woo YS; Bahk WM; Jon DI; Joo YH; Kim W; Seo JS; Ahn YM; Chung SK; Won SH; Shin YC; Yoon BH; Jung SH; Seok JH; Lee YS; Kim Y; Min KJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1147-52. PubMed ID: 19540298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
    Spina E; D'Arrigo C; Migliardi G; Santoro V; Muscatello MR; Micò U; D'Amico G; Perucca E
    Ther Drug Monit; 2006 Oct; 28(5):599-602. PubMed ID: 17038872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.